| Patents for A61P 7 - Drugs for disorders of the blood or the extracellular fluid (67,065) |
|---|
| 08/09/2001 | WO2001057020A1 INDOLE AND BENZIMIDAZOLE INHIBITORS OF FACTOR Xa |
| 08/09/2001 | WO2001057019A1 INDALONE AND BENZIMIDAZOLONE INHIBITORS OF FACTOR Xa |
| 08/09/2001 | WO2001057008A1 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors |
| 08/09/2001 | WO2001057003A1 3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE INHIBITORS OF FACTOR Xa |
| 08/09/2001 | WO2001056993A2 Pyrazole compositions useful as inhibitors of erk |
| 08/09/2001 | WO2001056607A1 Integrin expression inhibitors |
| 08/09/2001 | WO2001056598A2 Methods for preventing or attenuating pathoangiogenic conditions by using gbs-toxin (cm101) |
| 08/09/2001 | WO2001032596A8 Phenoxy carboxylic acid compounds and compositions for delivering active agents |
| 08/09/2001 | WO2001019814A3 Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment |
| 08/09/2001 | WO2001019788A3 BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa |
| 08/09/2001 | WO2001004318A3 Myxoma virus genes for immune modulation |
| 08/09/2001 | WO2001002017A3 Erythropoietin conjugates with polyethylenglycol |
| 08/09/2001 | WO2000078364A3 Extending the lifetime of anticoagulant oligodeoxynucleotide aptamers in blood |
| 08/09/2001 | WO2000073324A9 Modulation of gene expression in gastrointestinal inflammation |
| 08/09/2001 | WO2000071511A3 INHIBITORS OF FACTOR Xa |
| 08/09/2001 | WO2000070046A9 Secreted polypeptides and corresponding polynucleotides |
| 08/09/2001 | WO2000069257A3 Genetic modification of male germ cells for generation of transgenic species and genetic therapies |
| 08/09/2001 | WO2000066094A3 Use of compounds with a nitrogen-oxygen heterocycle as anti-infectious agents |
| 08/09/2001 | WO2000047554A3 INHIBITORS OF FACTOR Xa |
| 08/09/2001 | US20010012889 36 human secreted proteins |
| 08/09/2001 | US20010012837 Anti-ulcer composition |
| 08/09/2001 | US20010012834 Treating pulmonary disorders with gaseous agent causing repletion of GSNO |
| 08/09/2001 | CA2399686A1 Methods and materials relating to cub domain polypeptides and polynucleotides |
| 08/09/2001 | CA2399649A1 Methods and materials relating to leucine-rich repeat protein-like (lrr protein-like) polypeptides and polynucleotides |
| 08/09/2001 | CA2399274A1 3-aminopyrazole inhibitors of cyclin dependent kinases |
| 08/09/2001 | CA2399267A1 Protein c derivatives |
| 08/09/2001 | CA2399022A1 Ligand for vascular endothelial growth factor receptor |
| 08/09/2001 | CA2398754A1 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors |
| 08/09/2001 | CA2369076A1 Pyrazole compositions useful as inhibitors of erk |
| 08/09/2001 | CA2369050A1 Methods for preventing or attenuating pathoangiogenic conditions |
| 08/08/2001 | EP1121444A2 Protein kinase homologs |
| 08/08/2001 | EP1121430A1 Human isre-binding protein |
| 08/08/2001 | EP1121419A1 Tnfr related gene 12 |
| 08/08/2001 | EP1121376A1 Pregnane glucuronides |
| 08/08/2001 | EP1121349A1 Substituted thiadiazolsulfonamides used as interleukin-1-beta inhibitors |
| 08/08/2001 | EP1121346A1 New processes for producing beta-alanine derivative |
| 08/08/2001 | EP1121345A1 Esters of (+)-alpha-( 2,3- dimethoxyphenyl) -1- 2-(4- fluorophenyl) ethyl]-4- piperidinemethanol and their use as prodrugs of the 5ht2a receptor antagonist mdl 110,907 |
| 08/08/2001 | EP1121165A1 Method for production of stroma-free hemoglobin |
| 08/08/2001 | EP1121116A2 Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent |
| 08/08/2001 | EP0841918B1 Thrombin inhibitors |
| 08/08/2001 | CN1307522A Multi-action particle for structuring biological media |
| 08/08/2001 | CN1306848A Chinese medicine preparation for preventing and treating leucocytopenia and its preparation process |
| 08/08/2001 | CN1069321C New inhibitors of platelet aggregation |
| 08/08/2001 | CN1069319C Meso-monoiodo-substituted tetramacrocyclic compounds and methods for making and using the same |
| 08/08/2001 | CN1069316C Substituted 5-ring heterocycles, their preparation and use |
| 08/07/2001 | US6271374 Stable crystalline (6S)- and (6R)-tetrahydrofolic acid |
| 08/07/2001 | US6271367 Nucleotide sequences coding modulator of enzymatic activity; for use in the modulation of blood coagulation |
| 08/07/2001 | US6271353 Antibodies specific for human adseverin |
| 08/07/2001 | US6271261 Chemokine mediated diseases, binding interleukins or beta-receptors and administering to mammals |
| 08/07/2001 | US6271228 Blood pressure stabilization during hemodialysis |
| 08/07/2001 | US6271227 Anticoagulants |
| 08/07/2001 | US6271215 For humans or animals |
| 08/07/2001 | US6271200 Proteinic drug delivery system using aerosolized membrane-mimetic amphiphiles |
| 08/07/2001 | US6271025 Modified factor VIII cDNA |
| 08/07/2001 | US6270989 A homologous recombinant dna construct comprising a targeting sequence, an exogenous regulatory sequence, an exon and an unpaired splice donor site at the 3'end; gene therapy for thrombopoietin, thrombocytopenia, multiple sclerosis |
| 08/07/2001 | US6270779 Nitric oxide-releasing metallic medical devices |
| 08/07/2001 | US6270764 Therapy for a serious and debilitating disorder while avoiding complications such as bleeding tendency, toxicity and general side effects of currently available anti-coagulant agents. |
| 08/07/2001 | CA2051659C Platelet membrane microparticles |
| 08/07/2001 | CA2015296C Pyranyl cyanoguanidine derivatives |
| 08/02/2001 | WO2001055357A2 Myeloid colony stimulating factor and uses thereof |
| 08/02/2001 | WO2001055336A2 Methods and materials relating to cd84-like polypeptides and polynucleotides |
| 08/02/2001 | WO2001055333A2 Methods and materials relating to transforming growth factor alpha-like polypeptides and polynucleotides |
| 08/02/2001 | WO2001055219A2 scsCNTFR/NNT-1 FUSION PROTEIN |
| 08/02/2001 | WO2001055175A2 Process for the preparation of acetyl-amidiniophenylalanyl-cyclohexylglycyl-pyridinioalaninamides |
| 08/02/2001 | WO2001055172A2 ISOLATED COMPLEX COMPRISING A NNT-1 PROTEIN AND IN ADDITION AT LEAST A CLF-1 PROTEIN AND/OR A sCNTFRα PROTEIN |
| 08/02/2001 | WO2001055153A1 Clavams as protease inhibitors |
| 08/02/2001 | WO2001055149A1 Method for producing 6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1h-pyrrolizine-5-yl acetic acid |
| 08/02/2001 | WO2001055146A1 FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF |
| 08/02/2001 | WO2001055130A2 Novel 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for v1b and v1a arginine-vasopressin receptors |
| 08/02/2001 | WO2001055122A1 Dihydro-1,3,5-triazine amine derivatives and their therapeutic uses |
| 08/02/2001 | WO2001055115A1 Substituted nicotinamides and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| 08/02/2001 | WO2001055106A2 Novel melanocortin receptor agonists and antagonists |
| 08/02/2001 | WO2001055098A1 Palatable arginine compounds and uses thereof for cardiovascular health |
| 08/02/2001 | WO2001054686A2 L-arginine in combination with other compounds for treating cardiovascular diseases |
| 08/02/2001 | WO2001054676A2 Formulations for states of dehydration |
| 08/02/2001 | WO2001054667A1 Electrospun pharmaceutical compositions |
| 08/02/2001 | WO2001007065A3 PRODUCTION OF rhPBGD AND NEW THERAPEUTIC METHODS FOR TREATING PATIENTS WITH ACUTE INTERMITTENT PORPHYRIA (AIP) AND OTHER PORPHYRIC DISEASES |
| 08/02/2001 | WO2001004305A3 Human proteins involved in detoxification |
| 08/02/2001 | WO2001004146A3 Ecarin polypeptides, polynucleotides encoding ecarin, and methods for use thereof |
| 08/02/2001 | WO2000076971A3 Serine protease inhibitors |
| 08/02/2001 | WO2000069898A3 Molecular interactions in allergy cells |
| 08/02/2001 | WO2000047625A3 Humanized immunoglobulin reactive with b7 molecules and methods of treatment therewith |
| 08/02/2001 | WO1999066918A8 Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor |
| 08/02/2001 | US20010011077 Secreted cysteine rich protein-6 (SCRP-6); polynucleotides and processes for producing polypeptides |
| 08/02/2001 | US20010011072 Skin disorders; kidney and liver disorders |
| 08/02/2001 | US20010010934 Polypeptides that regulate epithelial specific gene expression; hypoproliferative disorders; medical diagnosis |
| 08/02/2001 | US20010010928 Protozoan expression system |
| 08/02/2001 | US20010010913 Isolated polypeptide |
| 08/02/2001 | US20010010818 Methods and formulations for reducing circulating antibodies |
| 08/02/2001 | US20010010815 Adeno-associated vector compositions for expression of factor VIII |
| 08/02/2001 | CA2398728A1 Novel melanocortin receptor agonists and antagonists |
| 08/02/2001 | CA2398546A1 Methods and materials relating to cd84-like polypeptides and polynucleotides |
| 08/02/2001 | CA2398396A1 Methods and materials relating to transforming growth factor alpha-like polypeptides and polynucleotides |
| 08/02/2001 | CA2397493A1 Substituted nicotinamides and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| 08/02/2001 | CA2396640A1 Electrospun pharmaceutical compositions |
| 08/02/2001 | CA2395447A1 Palatable arginine compounds and uses thereof for cardiovascular health |
| 08/02/2001 | CA2395446A1 Compositions, kits, and methods for cardiovascular health |
| 08/01/2001 | EP1119620A2 Polynucleotides coding for secreted polypeptides. some having similarity to syncollin or claudin or cytokine. their therapeutic uses |
| 08/01/2001 | EP1119566A1 Novel heterocyclyl-methyl-substituted pyrazoles |
| 08/01/2001 | EP1119353A1 Compositions and methods of inhibiting neoplastic diseases with compounds related to limocitrin and 5-desmethyl sinensetin |